BRACAnalysis CDx

January 7, 2019

BRACAnalysis CDx Approved in US as Companion Diagnostic Test for First-line Lynparza Treatment

News

Myriad Genetics‘ BRACAnalysis CDx has been approved by the U.S. Food and Drug Administration as a companion diagnostic test to identify women with ovarian cancer eligible for first-line maintenance treatment with Lynparza (olaparib). ... Read more

April 28, 2017April 28, 2017

Myriad, Clovis to Jointly Support Regulatory Development of Advanced Ovarian Cancer Therapy Rubraca

News

Myriad Genetics will support the post-marketing regulatory development of Clovis Oncology‘s drug Rubraca (rucaparib) to treat women with BRCA-positive advanced ovarian cancer who have already received two or more chemotherapies. The U.S. Food and Drug ... Read more